[Sensitivity tests of anti-cancer drugs with human tumor stem cell assay. 2. The results in renal cell carcinoma and urothelial carcinoma].
D015250:Aclarubicin / Q000031:analogs & derivatives*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002292:Carcinoma, Renal Cell / Q000473:pathology*; D002295:Carcinoma, Transitional Cell / Q000473:pathology*; D003114:Colony-Forming Units Assay; D004317:Doxorubicin / Q000494:pharmacology; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007680:Kidney Neoplasms / Q000473:pathology*; D007682:Kidney Pelvis; D009279:Naphthacenes / Q000494:pharmacology; D014410:Tumor Stem Cell Assay; D001749:Urinary Bladder Neoplasms / Q000473:pathology*; D014747:Vinblastine / Q000494:pharmacology
D000970:Antineoplastic Agents; D009279:Naphthacenes; C011157:aclacinomycins; D014747:Vinblastine; D015250:Aclarubicin; D004317:Doxorubicin